title: An open pilot study of nefazodone in depression with anger attacks: relationship between clinical response and receptor binding.
abstract: Nefazodone has been widely used as an antidepressant, but it has not been tested for depression with anger attacks. In an open study, we administered nefazodone (maximum 600 mg/day) for 12 weeks to 16 outpatients who had major depression with anger attacks. Assessment instruments comprised the Structured Clinical Interview for DSM-IV (SCID), Anger Attacks Questionnaire (AAQ), 17-item Hamilton Rating Scale for Depression (HAM-D-17), Clinician Global Impression Scale (CGI), Symptom Questionnaire (SQ), Modified Overt Aggression Scale (MOAS), and MOAS-Self-Rated. Three subjects underwent positron emission tomography (PET) with [18F]-setoperone for 5-HT2 binding potential (BP) and [11C]-SCH-23,390 for D1 BP, both at baseline and after 6 weeks of treatment. Eight subjects underwent PET with [18F]-setoperone and with [11C]-SCH-23,390 at baseline only. In an examination of whether D1 and 5HT2 (data available in six subjects) receptor BP predicted treatment response, we found significant decreases in the HAM-D-17, CGI-S, weighted MOAS, MOAS verbal scale, OAS Self-Rated verbal, SQ Depression and Anger/Hostility scales after nefazodone; 50% responded to nefazodone (defined as >or=50% decrease in HAM-D-17 score), and 44% reported disappearance of anger attacks. A statistically significant percentage decrease in 5HT2 BP was observed for the right mesial frontal and left parietal regions after 6 weeks of treatment. No significant change was observed in D1 BP in any region. Although CGI-I scores correlated significantly with D1 BP in the left thalamic region, the correlation was not significant after Bonferroni correction. The effectiveness of nefazodone for depression with anger attacks may be related to widespread changes in 5HT2 receptor BP.
authors.affiliation: Department of Psychiatry, Massachusetts General Hospital, 15 Parkman Street, WAC 812, Boston, MA 02114, USA. dmischoulon@partners.org
authors.forename: David
authors.initials: D
authors.lastname: Mischoulon
authors.forename: Darin D
authors.initials: DD
authors.lastname: Dougherty
authors.forename: Kathryn A
authors.initials: KA
authors.lastname: Bottonari
authors.forename: Robert L
authors.initials: RL
authors.lastname: Gresham
authors.forename: Shamsah B
authors.initials: SB
authors.lastname: Sonawalla
authors.forename: Alan J
authors.initials: AJ
authors.lastname: Fischman
authors.forename: Maurizio
authors.initials: M
authors.lastname: Fava
mesh_terms: D000328:Adult; D000786:Anger; D018687:Antidepressive Agents, Second-Generation / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D001665:Binding Sites; D001921:Brain / Q000378:metabolism*; D003863:Depression / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D010865:Pilot Projects; D010879:Piperazines; D011954:Receptors, Dopamine / Q000378:metabolism*; D011985:Receptors, Serotonin / Q000378:metabolism*; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires; D013788:Thalamus / Q000378:metabolism; D014055:Tomography, Emission-Computed; D014230:Triazoles / Q000493:pharmacokinetics* / Q000627:therapeutic use*
chemical_list: D018687:Antidepressive Agents, Second-Generation; D010879:Piperazines; D011954:Receptors, Dopamine; D011985:Receptors, Serotonin; D014230:Triazoles; C051752:nefazodone